vimarsana.com

Page 2 - புற்றுநோய் ஆராய்ச்சி ஆண்டு News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Here s Why Shares of Affimed Skyrocketed Today

Shares of drugmaker Affimed (NASDAQ:AFMD) are up 19% at 2:06 p.m. EDT after the company disclosed positive data from an early-stage clinical trial of its innate cell engager AFM13 in patients with Hodgkin s lymphoma. So what The data release only included results from the first four patients in the study, but they were impressive nonetheless. All four patients responded to the therapy, which included giving the patients immune cells called natural killer (NK) cells and AFM13 that attracts the NK cells to the tumor cells. Two patients had a complete response, while the other two had a partial response. Adding to the impressiveness, these patients had already failed between four and 14 different lines of therapy before being given the NK cells plus AFM13.

SOTIO to Present Preclinical Results Describing SOT102 as Treatment of Solid Tumors at the American Association of Cancer Research Annual Meeting

SOTIO to Present Preclinical Results Describing SOT102 as Treatment of Solid Tumors at the American Association of Cancer Research Annual Meeting , a clinical stage immuno-oncology company owned by PPF Group, today announced American Association of Cancer Research Annual Meeting . The presentation focuses on treatment of CLDN18.2-expressing solid tumors. SOT102 (earlier SO-N102) is a CLDN18.2 targeting antibody-drug conjugate based on a novel proprietary, highly-specific monoclonal antibody conjugated to a potent cytotoxic drug molecule exhibiting strong anti-tumor activity. SOT102 was studied in models of various CLDN18.2-positive solid tumors, mainly of gastric and pancreatic origin. Poster Presentation details: Title: SOT102, a novel CLDN18.2-targeting antibody-drug conjugate with strong anti-tumor effect in various solid tumors expressing low target levels

Investegate |Sotio Announcements | Sotio: SOTIO to Present Preclinical Results Describing SOT102 as Treatment of Solid Tumors at the American Association of Cancer Research Annual Meeting

A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient: 1. Obtains access to the information in a personal capacity; 2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services; 3. Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body; 4. Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.